Johnson & Johnson (NYSE: JNJ) has disclosed the results from the real-world study on the durability of COVID-19 vaccines in the United States. Results demonstrated that a single shot of the Johnson & Johnson COVID-19 vaccine provided protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions.   Supporting Data  The new study, sponsored by Janssen, a J&J company, evaluated the durability profiles for all three vaccines authorized or approved in the U.S. across three categories; infections, hospitalizations, and ICU admissions.  Per the study, the Johnson & Johnson COVID-19 vaccine remained durable against breakthrough infections and hospitalizations, while the mRNA vaccines (two-doses) showed decreasing effectiveness for both.
https://www.tipranks.com/news/johnson-johnsons-single-dose-of-covid-19-vaccine-protects-for-6-months?utm_source=advfn.com&utm_medium=referral
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Johnson and Johnson Charts.